You are here: Industry Insights > Merck

News List

Roche's Tecentriq cocktail hops into the FDA fast lane for another Merck showdown fiercepharma
May 08, 2018
The company said Monday that the triplet won FDA priority review for previously untreated patients with advanced lung cancer, and that means it could go toe-to-toe with Merck & Co. by Sept. 5.
Merck invests in Moderna pharmatimes
May 07, 2018
Merck is investing $125 million in Moderna under a new deal that expands the firms’ 2016 partnership to develop messenger RNA cancer vaccines.
Merck's MS treatment shows promise in new data pharmatimes
May 03, 2018
New data published in The Multiple Sclerosis Journal has shown more promising results for Merck's MS treatment Mavenclad (cladribine tablets) on two subgroups of patients with highly active relapsing multiple sclerosis.
Merck Foundation, MAHE to train embryologists from Africa and Asia biospectrumasia
April 20, 2018
The training program will shoulder the responsibility of fine-tuning and honing the delicate skills of the embryologists in IVF Centres.
Merck and NewLink's Ebola Vaccine Leads the Pack in Offering Longest Protection biospace
April 19, 2018
Several companies have developed vaccines to the deadly Ebola virus that are effective, but public health officials and scientists have had concerns about how long those vaccines’ protection lasts.
Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine biospace
April 18, 2018
Mercktoday announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.
Merck May Have Too Many Eggs in Its Keytruda Basket biospace
April 17, 2018
In 2017, Merck & Co.’s wonder drug, Keytruda (pembrolizumab), brought in $3.8 billion, or about 9 percent of the company’s total revenue.
Merck & Co. details positive late-stage data for Keytruda in adjuvant melanoma firstwordpharma
April 16, 2018
Merck & Co. announced Sunday that Keytruda significantly prolonged recurrence-free survival, reducing the risk of disease recurrence or death by 43 percent compared to placebo, in a Phase III study as adjuvant therapy in patients with resected
Final guidance from NICE on Merck, Pfizer’s Bavencio pharmatimes
April 13, 2018
The National Institute for Health and Care Excellence has now published final guidelines endorsing Merck and Pfizer’s Bavencio as an option for patients with Merkel cell carcinoma (MCC).
Merck Helps Accelerate Global Access to Affordable Vaccines prnasia
April 13, 2018
Merck, a leading science and technology company today announced a partnership with Oxford University's Jenner Institute to develop more robust and scalable vaccine manufacturing processes.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page